Prospective Registry on Mesothelioma Peritonei Treatment (PROMPT): Study design and rationale

Christopher Cao; Tristan D. Yan; David L. Morris; Kurt Van Der Speeten; Søren Laurberg; Olivier Glehen; Karl Link; Pompiliu Piso; Antonios Apostolos K Tentes; Marcello Deraco; Stein G. Larsen; Dragutin Kecmanovic; Luis G. Bayón; Juan T. Melero; Santiago González-Moreno; Haile Mahteme; Philippe Gertsch; Brendan Moran; Jesus Esquivel; Richard Alexander; Edward A. Levine; Paul H. Sugarbaker

doi:10.1700/1053.11517

Prospective Registry on Mesothelioma Peritonei Treatment (PROMPT): Study design and rationale

Christopher Cao, Tristan D. Yan^*, David L. Morris, Kurt Van Der Speeten, Søren Laurberg, Olivier Glehen, Karl Link, Pompiliu Piso, Antonios Apostolos K Tentes, Marcello Deraco, Stein G. Larsen, Dragutin Kecmanovic, Luis G. Bayón, Juan T. Melero, Santiago González-Moreno, Haile Mahteme, Philippe Gertsch, Brendan Moran, Jesus Esquivel, Richard AlexanderEdward A. Levine, Paul H. Sugarbaker

^*Corresponding author for this work

Research output: Contribution to journal › Short survey

2 Citations (Scopus)

Abstract

Diffuse malignant peritoneal mesothelioma (DMPM) is an aggressive and rare form of cancer arising from the mesothelial lining of the peritoneum. Due to the latency period between asbestos exposure and disease progression, the peak in incidence of DMPM is likely to occur in the coming decade for many industrialized nations, with a multitude of industrial, medico-legal and health-related implications^1,2. Traditional therapeutic modalities such as systemic chemotherapy and radiotherapy have not been proven to be effective in the treatment of DMPM, and patients diagnosed with the disease have a life expectancy of less than 12 months^3-5. Combined treatment involving cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has been utilized in several specialized centers around the world and has been found to be a feasible procedure with encouraging survival outcomes^6-8.

Original language	English
Pages (from-to)	166-171
Number of pages	6
Journal	Tumori
Volume	98
Issue number	1
DOIs	https://doi.org/10.1700/1053.11517
Publication status	Published - Jan 2012
Externally published	Yes

Access to Document

10.1700/1053.11517

Cite this

Cao, C., Yan, T. D., Morris, D. L., Van Der Speeten, K., Laurberg, S., Glehen, O., Link, K., Piso, P., Tentes, A. A. K., Deraco, M., Larsen, S. G., Kecmanovic, D., Bayón, L. G., Melero, J. T., González-Moreno, S., Mahteme, H., Gertsch, P., Moran, B., Esquivel, J., ... Sugarbaker, P. H. (2012). Prospective Registry on Mesothelioma Peritonei Treatment (PROMPT): Study design and rationale. Tumori, 98(1), 166-171. https://doi.org/10.1700/1053.11517

@article{6389f5f47c074d94bbcf5c3f768e68ce,

title = "Prospective Registry on Mesothelioma Peritonei Treatment (PROMPT): Study design and rationale",

abstract = "Diffuse malignant peritoneal mesothelioma (DMPM) is an aggressive and rare form of cancer arising from the mesothelial lining of the peritoneum. Due to the latency period between asbestos exposure and disease progression, the peak in incidence of DMPM is likely to occur in the coming decade for many industrialized nations, with a multitude of industrial, medico-legal and health-related implications1,2. Traditional therapeutic modalities such as systemic chemotherapy and radiotherapy have not been proven to be effective in the treatment of DMPM, and patients diagnosed with the disease have a life expectancy of less than 12 months3-5. Combined treatment involving cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has been utilized in several specialized centers around the world and has been found to be a feasible procedure with encouraging survival outcomes6-8.",

author = "Christopher Cao and Yan, {Tristan D.} and Morris, {David L.} and {Van Der Speeten}, Kurt and S{\o}ren Laurberg and Olivier Glehen and Karl Link and Pompiliu Piso and Tentes, {Antonios Apostolos K} and Marcello Deraco and Larsen, {Stein G.} and Dragutin Kecmanovic and Bay{\'o}n, {Luis G.} and Melero, {Juan T.} and Santiago Gonz{\'a}lez-Moreno and Haile Mahteme and Philippe Gertsch and Brendan Moran and Jesus Esquivel and Richard Alexander and Levine, {Edward A.} and Sugarbaker, {Paul H.}",

year = "2012",

month = jan,

doi = "10.1700/1053.11517",

language = "English",

volume = "98",

pages = "166--171",

journal = "Tumori",

issn = "0300-8916",

publisher = "Wichtig Publishing",

number = "1",

}

Cao, C, Yan, TD, Morris, DL, Van Der Speeten, K, Laurberg, S, Glehen, O, Link, K, Piso, P, Tentes, AAK, Deraco, M, Larsen, SG, Kecmanovic, D, Bayón, LG, Melero, JT, González-Moreno, S, Mahteme, H, Gertsch, P, Moran, B, Esquivel, J, Alexander, R, Levine, EA & Sugarbaker, PH 2012, 'Prospective Registry on Mesothelioma Peritonei Treatment (PROMPT): Study design and rationale', Tumori, vol. 98, no. 1, pp. 166-171. https://doi.org/10.1700/1053.11517

TY - JOUR

T1 - Prospective Registry on Mesothelioma Peritonei Treatment (PROMPT)

T2 - Study design and rationale

AU - Cao, Christopher

AU - Yan, Tristan D.

AU - Morris, David L.

AU - Van Der Speeten, Kurt

AU - Laurberg, Søren

AU - Glehen, Olivier

AU - Link, Karl

AU - Piso, Pompiliu

AU - Tentes, Antonios Apostolos K

AU - Deraco, Marcello

AU - Larsen, Stein G.

AU - Kecmanovic, Dragutin

AU - Bayón, Luis G.

AU - Melero, Juan T.

AU - González-Moreno, Santiago

AU - Mahteme, Haile

AU - Gertsch, Philippe

AU - Moran, Brendan

AU - Esquivel, Jesus

AU - Alexander, Richard

AU - Levine, Edward A.

AU - Sugarbaker, Paul H.

PY - 2012/1

Y1 - 2012/1

N2 - Diffuse malignant peritoneal mesothelioma (DMPM) is an aggressive and rare form of cancer arising from the mesothelial lining of the peritoneum. Due to the latency period between asbestos exposure and disease progression, the peak in incidence of DMPM is likely to occur in the coming decade for many industrialized nations, with a multitude of industrial, medico-legal and health-related implications1,2. Traditional therapeutic modalities such as systemic chemotherapy and radiotherapy have not been proven to be effective in the treatment of DMPM, and patients diagnosed with the disease have a life expectancy of less than 12 months3-5. Combined treatment involving cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has been utilized in several specialized centers around the world and has been found to be a feasible procedure with encouraging survival outcomes6-8.

AB - Diffuse malignant peritoneal mesothelioma (DMPM) is an aggressive and rare form of cancer arising from the mesothelial lining of the peritoneum. Due to the latency period between asbestos exposure and disease progression, the peak in incidence of DMPM is likely to occur in the coming decade for many industrialized nations, with a multitude of industrial, medico-legal and health-related implications1,2. Traditional therapeutic modalities such as systemic chemotherapy and radiotherapy have not been proven to be effective in the treatment of DMPM, and patients diagnosed with the disease have a life expectancy of less than 12 months3-5. Combined treatment involving cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has been utilized in several specialized centers around the world and has been found to be a feasible procedure with encouraging survival outcomes6-8.

UR - http://www.scopus.com/inward/record.url?scp=84863185846&partnerID=8YFLogxK

U2 - 10.1700/1053.11517

DO - 10.1700/1053.11517

M3 - Short survey

C2 - 22495719

AN - SCOPUS:84863185846

SN - 0300-8916

VL - 98

SP - 166

EP - 171

JO - Tumori

JF - Tumori

IS - 1

ER -

Prospective Registry on Mesothelioma Peritonei Treatment (PROMPT): Study design and rationale

Abstract

Access to Document

Other files and links

Fingerprint

Cite this